
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
解锁市场时间线与信号动态
最近 90 天内有 6 个信号。
该公司进入各个市场的顺序 — 从最早到最新
Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO
Director, Medical Affairs
注册以查看完整信号动态
Alnylam Pharmaceuticals 的国际扩张与竞争对手的对比情况
条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
Alnylam Pharmaceuticals你 | 5 | 2 | 0% | 6 | 33 |
Scientist, Process Sciences
查看职位Cambridge, MA · 上周
Medical Science Liaison, Lead (Associate Director) - Italy
查看职位Greater Rome Metropolitan Area · 上周
Medical Science Liaison, Lead (Associate Director) - Italy
查看职位Milan, Lombardy, Italy · 上周
没有进行中的营销活动
注册以跟踪该公司,并在发生变化时第一时间获得提醒。
纳斯达克宣布自2025年12月22日起,将有六家公司加入纳斯达克100指数,包括Alnylam制药和Ferrovial SE。
纳斯达克100指数上涨1.58%,半导体股大幅反弹。美光科技领涨9.87%,KLAC、AMAT、ASML等芯片设备制造商也大幅上涨。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Alnylam Pharmaceuticals 的业务、市场和增长信号的快速解答。
